Suppression of HBV replication by the expression of nickase- and nuclease dead-Cas9

[1]  Tetsushi Sakuma,et al.  Highly multiplexed CRISPR‐Cas9‐nuclease and Cas9‐nickase vectors for inactivation of hepatitis B virus , 2016, Genes to cells : devoted to molecular & cellular mechanisms.

[2]  David Cyranoski,et al.  Chinese scientists to pioneer first human CRISPR trial , 2016, Nature.

[3]  Sara Reardon,et al.  First CRISPR clinical trial gets green light from US panel , 2016, Nature.

[4]  K. Peggs,et al.  First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL , 2015 .

[5]  J. Hauber,et al.  CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X , 2015, Scientific Reports.

[6]  David A. Scott,et al.  CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus , 2015, Scientific Reports.

[7]  B. Cullen,et al.  Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. , 2015, Virology.

[8]  Hidemasa Bono,et al.  CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites , 2014, Bioinform..

[9]  C. Seeger,et al.  Targeting Hepatitis B Virus With CRISPR/Cas9 , 2014, Molecular therapy. Nucleic acids.

[10]  Ding-Shinn Chen,et al.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo , 2014, Molecular therapy. Nucleic acids.

[11]  V. Iyer,et al.  Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects , 2014, Nature Methods.

[12]  Jeffry D. Sander,et al.  CRISPR-Cas systems for editing, regulating and targeting genomes , 2014, Nature Biotechnology.

[13]  H. Kusuhara,et al.  Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP) , 2014, Hepatology.

[14]  T. Liang,et al.  Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA , 2014, Science.

[15]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[16]  Yoshitaka Fujihara,et al.  Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA , 2013, Scientific Reports.

[17]  David A. Scott,et al.  Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity , 2013, Cell.

[18]  David R. Liu,et al.  High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity , 2013, Nature Biotechnology.

[19]  Eli J. Fine,et al.  DNA targeting specificity of RNA-guided Cas9 nucleases , 2013, Nature Biotechnology.

[20]  J. Keith Joung,et al.  High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.

[21]  Luke A. Gilbert,et al.  Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.

[22]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[23]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[24]  Wenhui Li,et al.  Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus , 2012, eLife.

[25]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[26]  J. Vogel,et al.  CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III , 2011, Nature.

[27]  F. Zoulim.  Hepatitis B virus resistance to antiviral drugs: where are we going? , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[28]  J. Dienstag,et al.  Hepatitis B Virus Infection , 2010 .

[29]  R. Barrangou,et al.  CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes , 2007, Science.

[30]  N. Izumi,et al.  Influence of hepatitis B virus genotypes on the intra‐ and extracellular expression of viral DNA and antigens , 2006, Hepatology.

[31]  P. Schirmacher,et al.  Peginterferon alpha‐2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B , 2006, Hepatology.

[32]  W. M. Lee,et al.  Hepatitis B virus infection. , 1997, The New England journal of medicine.

[33]  H. Sakugawa,et al.  Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. , 1988, The Journal of general virology.

[34]  G. Acs,et al.  Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Varmus,et al.  The molecular biology of the hepatitis B viruses. , 1987, Annual review of biochemistry.